Zobrazeno 1 - 10
of 204
pro vyhledávání: ''
Autor:
Kosei Hirakawa, Yuki Okazaki, Masatsune Shibutani, Shinichiro Kashiwagi, Masaichi Ohira, Wang En, Yasuhito Iseki, Tatsunari Fukuoka
Publikováno v:
Anticancer Research. 41:6211-6216
Background/aim Recently, trifluridine/tipiracil (FTD/TPI) treatment was established as a later-line treatment for metastatic colorectal cancer (mCRC). However, FTD/TPI treatment is frequently associated with hematological toxicity. The aim of this st
Autor:
Ichio Aoki, Zhivko Zhelev, Dessislava Lazarova, Sayaka Shibata, Thomas Miller, Genoveva Zlateva, Rumiana Bakalova, Akira Sumiyoshi
Publikováno v:
Anticancer Research. 41:6067-6076
Background/aim We describe a pharmacological strategy for selectively targeting glioblastoma using a redox-active combination drug menadione/ascorbate (M/A), compared to the chemotherapeutic standard-of-care temozolomide (TMZ). Materials and methods
Autor:
Jun Yamamoto, Junichi Kurebayashi, Wataru Saito, Robert M. Hoffman, Tsunehisa Nomura, Takuya Murata, Takuya Moriya, Chihiro Hozumi
Publikováno v:
Anticancer Research. 41:6191-6197
Background Matrix-producing breast carcinoma (MPBC) is a very rare and usually aggressive triple-negative breast cancer. We successfully established a patient-derived orthotopic xenograft (PDOX) model from a patient with MPBC and used it to study tum
Autor:
Shogo Teraoka, Atsushi Takenaka, Katsuya Hikita, Masashi Honda, Hideto Iwamoto, Shuichi Morizane, Bunya Kawamoto, Noriya Yamaguchi, Tetsuya Yumioka, Ryutaro Shimizu
Publikováno v:
Anticancer Research. 41:5767-5773
BACKGROUND This study aimed to investigate the response to platinum-based chemotherapy rechallenge in patients with pembrolizumab-refractory urothelial carcinoma. PATIENTS AND METHODS We retrospectively reviewed 14 patients with pembrolizumab-refract
Publikováno v:
Anticancer Research. 41:5729-5737
Background/aim This study aimed to identify the predictive markers for carboplatin-induced severe thrombocytopenia. Patients and methods We conducted a retrospective cohort analysis of inpatients who received carboplatin and pemetrexed. Results Among
Autor:
Angiolo Gadducci, Stefania Cosio
Publikováno v:
Anticancer Research. 41:4673-4685
Platinum/paclitaxel-based chemotherapy is able to obtain a clinical response in up to 80% of patients with advanced ovarian carcinoma, but most of them will subsequently develop recurrent disease. Several therapeutic approaches, including prolonged a
Publikováno v:
Anticancer Research. 41:4313-4319
BACKGROUND/AIM In order to produce an animal model for oral mucositis induced by anticancer drugs, it is necessary to maintain an immunosuppressive state. We determined the optimal dose and frequency of 5-fluorouracil for a model mouse production. In
Autor:
Hiroshi Tsubamoto, Y Takimoto, Tomoko Ueda, Hiroaki Shibahara, R Isono, Masakazu Shinohara, Kayo Inoue, Kazuko Sakata
Publikováno v:
Anticancer Research. 41:4271-4276
Background/aim The anticancer mechanism of itraconazole remains unsolved; therefore, we studied itraconazole-induced alterations in specialized pro-resolving mediators (SPMs) in cancer cells. Materials and methods The human cervical squamous carcinom
Publikováno v:
Anticancer Research. 41:3769-3778
BACKGROUND/AIM Cholangiocarcinoma is a lethal disease with increasing incidence worldwide. New therapeutic compounds are urgently needed for this disease. Here, the inhibitory effect of adenosine on cholangiocarcinoma cells was studied. MATERIALS AND
Autor:
Christian Thomas, Nadine Gelbrich, Alexander Mustea, Matthias B Stope, Maria A Oster, Holger H.H. Erb, Clemens Cammann
Publikováno v:
Anticancer Research. 41:3271-3279
Background/aim Androgen receptor (AR) degradation is the primary regulator of androgen receptor activity. This study was designed to investigate the influence of the proteasome on AR protein stability after enzalutamide (Enz) treatment. Materials and